- Home
- HQI vs KLRS Comparison
HQI vs KLRS Comparison
Compare HQI & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQI
- KLRS
- Stock Information
- Founded
- HQI 2002
- KLRS 2019
- Country
- HQI United States
- KLRS United States
- Employees
- HQI N/A
- KLRS N/A
- Industry
- HQI Professional Services
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HQI Consumer Discretionary
- KLRS Health Care
- Exchange
- HQI Nasdaq
- KLRS Nasdaq
- Market Cap
- HQI 143.3M
- KLRS 129.0M
- IPO Year
- HQI N/A
- KLRS N/A
- Fundamental
- Price
- HQI $10.03
- KLRS $2.50
- Analyst Decision
- HQI Strong Buy
- KLRS Buy
- Analyst Count
- HQI 2
- KLRS 1
- Target Price
- HQI $16.00
- KLRS N/A
- AVG Volume (30 Days)
- HQI 14.9K
- KLRS 38.9K
- Earning Date
- HQI 08-07-2025
- KLRS 08-15-2025
- Dividend Yield
- HQI 2.34%
- KLRS N/A
- EPS Growth
- HQI N/A
- KLRS N/A
- EPS
- HQI 0.24
- KLRS N/A
- Revenue
- HQI $33,651,000.00
- KLRS N/A
- Revenue This Year
- HQI N/A
- KLRS N/A
- Revenue Next Year
- HQI $4.99
- KLRS N/A
- P/E Ratio
- HQI $38.53
- KLRS N/A
- Revenue Growth
- HQI N/A
- KLRS N/A
- 52 Week Low
- HQI $9.04
- KLRS $2.28
- 52 Week High
- HQI $15.75
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- HQI 47.95
- KLRS N/A
- Support Level
- HQI $10.20
- KLRS N/A
- Resistance Level
- HQI $10.41
- KLRS N/A
- Average True Range (ATR)
- HQI 0.20
- KLRS 0.00
- MACD
- HQI 0.02
- KLRS 0.00
- Stochastic Oscillator
- HQI 39.68
- KLRS 0.00
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.